Bone density and metabolism in subjects with microdeletion of chromosome 22q11 (del22q11)

European Journal of Endocrinology

Volumn 163, Issue 2, 2010, Pages 329-337

  Stagi, Stefano ^a   Lapi, Elisabetta ^b   Gambineri, Eleonora ^a   Manoni, Cristina ^a   Genuardi, Maurizio ^b   Colarusso, Gloria ^a   Conti, Camilla ^a   Chiarelli, Francesco ^c   De Martino, Maurizio ^a   Azzari, Chiara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHILD; CHROMOSOME 22Q; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; URINE LEVEL; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE AND BONES; BONE DENSITY; CALCIUM; CHILD; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; HUMANS; MALE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; VITAMIN D;

EID: 77955394161     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0167     Document Type: Article

References (32)

1. Oskarsdottir S, Vujic M & Fast A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Archives of Disease in Childhood 2004 89 148-151.
2. Yamagishi H & Srivastava D. Unraveling the genetic and developmental mysteries of 22q11 deletion syndrome. Trends in Molecular Medicine 2003 9 383-389.
3. Robin N & Shprintzen R. Defining the clinical spectrum of deletion 22q11.2. Journal of Pediatrics 2005 147 90-96. (Pubitemid 40981151)
4. Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, Schuffenhauer S, Oechsler H, Belohradsky B, Prieur M, Aurias A, Raymond FL, Clayton-Smith J, Hatchwell E, McKeown C, Beemer FA, Dallapiccola B, Novelli G, Hurst JA, Ignatius J, Green AJ, Winter RM, Brueton L, Brondum-Nielsen K, Stewart F, Van Essen T, Patton M, Paterson J & Scambler PJ. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. Journal of Medical Genetics 1997 34 798-804.
5. Brauner R, Le Harivel de Gonneville A, Kindermans C, Le Bidois J, Prieur M, Lyonnet S & Souberbielle JC. Parathyroid function and growth in 22q11.2 deletion syndrome. Journal of Pediatrics 2003 142 504-508.
6. Schoenau E, Land C, Stabrey A, Remer T & Kroke A. The bone mass concept: problems in short stature. European Journal of Endocrinology 2004 151 (Suppl 1) S87-S91. (Pubitemid 39276354)
7. Katzman DK, Bachrach LK, Carter DR & Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. Journal of Clinical Endocrinology and Metabolism 1991 73 1332-1339.
8. Kröger H, Kotaniemi A, Vainio P & Alhava E. Bone densitometry of the spine and femur in children by dual-energy X-ray absorptiometry. Bone and Mineral 1992 17 75-85.
9. de Lind van Wijngaarden RF, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, van Leeuwen M, Haring DA, Bocca G, Mieke Houdijk EC & Hokken-Koelega AC. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2009 94 3763-3771.
10. Boot AM, Engels MA, Boerma GJ, Krenning EP & De Muinck Keizer-Schrama SM. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2423-2428.
11. Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J, Odink RJ, Reeser M, Rongen-Westerlaken C, Stokvis-Brantsma WH, Waelkens JJ & Hokken-Koelega AC. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clinical Endocrinology 2007 67 485-492.
12. Walther F, Fusch C, Radke M, Beckert S & Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. Journal of Pediatric Gastroenterology and Nutrition 2006 43 42-51. (Pubitemid 44022385)
13. Benbassat CA, Eshed V, Kamjin M & Laron Z. Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities Journal of Clinical Endocrinology and Metabolism 2003 88 4586-4589.
14. Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, Falcini F & Chiarelli F. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. European Journal of Endocrinology 2005 153 879-885.
15. Nicoletti I. Normal and Pathological Auxology, pp 289-304. Firenze: Centro Studi Auxologici, 1994.
16. Greulich WW & Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, edn 2. Stanford Univ. Press: Stanford, CA, USA 1959.
17. Tanner JM & Whitehouse RH. Clinical longitudinal standards for height, weight height velocity, weight velocity and stages of puberty. Archives of Disease in Childhood 1976 51 170-179.
18. Weinzimer SA. Endocrine aspects of the 22q11.2 deletion syndrome. Genetics in Medicine 2001 3 19-22.
19. Kroger H, Vainio P, Nieminen J & Kotaniemi A. Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 1995 17 157-159.
20. Cuneo B, Driscoll D, Gidding S & Langman C. Evolution of latent hypoparathyroidism in familial 22q11 deletion syndrome. American Journal of Medical Genetics 1997 69 50-55. (Pubitemid 27111180)
21. McDonald-McGinn DM, Kirschner R, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, Moss E, Solot C, Wang P, Jacobs I, Handler S, Knightly C, Haher K, Wilson M, Ming JE, Grace K, Driscoll D, Pasquariello P, Randall P, Larossa D, Emanuel BS & Zackai EH. The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genetic Counseling 1999 10 11-24.
22. Hiéronimus S, Bec-Roche M, Pedeutour F, Lambert JC, Wagner-Malher K, Mas JC, Sadoul JL & Fénichel P. The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11. European Journal of Endocrinology 2006 155 47-52.
23. Ruiz JC, Mandel C & Garabedian M. Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents. Journal of Bone and Mineral Research 1995 95 675-679.
24. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. Journal of the American Medical Association 1994 272 1942-1948.
25. Karlsson MK, Linden C, Karlsson C, Johnell O, Obrant K & Seemann E. Exercise during growth and bone mineral density and fractures in old age. Lancet 2000 355 469-470.
26. Karlsson KM, Karlsson C, Ahlborg HG, Valdimarsson O, Ljunghall S & Obrant KJ. Bone turnover responses to changed physical activity. Calcified Tissue International 2003 72 675-680. (Pubitemid 36917321)
27. Kaufman JM, Ostertag A, Saint-Pierre A, Cohen-Solal M, Boland A, Van Pottelbergh I, Toye K, de Vernejoul MC & Martinez M. Genome-wide linkage screen of bone mineral density (BMD) in European pedigrees ascertained through a male relative with low BMD values: evidence for quantitative trait loci on 17q21-23, 11q12-13, 13q12-14, and 22q11. Journal of Clinical Endocrinology and Metabolism 2008 93 3755-3762.
28. Miao D, Li J, Xue Y, Su H, Karaplis AC & Goltzman D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 2004 145 3554-3562.
29. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A & Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 2003 88 569-575.
30. Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ & Karsenty G. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000 406 199-203.
31. Bachrach L. Acquisition of optimal bone mass in childhood and adolescence. Trends in Endocrinology and Metabolism 2001 12 22-28. (Pubitemid 33713182)
32. Mora S & Gilsanz V. Establishment of peak bone mass. Endocrinology and Metabolism Clinics of North America 2003 32 39-63.